ATHE — ALTERITY THERAPEUTICS LTD

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1131343 · Australia
Last close
$3.50
Market Cap
$63.73M
52W High
$5.89
52W Low
$2.66
ADV30
17,866
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 46,019,461 37,317,962 3,294,499
Dec 2025 — — — — 56,918,905 49,200,547 2,650,906
Jun 2025 — — — — 46,026,360 33,158,642 3,623,274
Dec 2024 — — — — 10,546,933 4,536,559 2,760,926

Balance + Analyst (yfinance extras)

Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,610,016
EBITDA
$-25,090,684
Free Cash Flow
$-14,740,514
Enterprise Value
$36,619,396
Total Cash
$37,317,960
Total Debt
$193,465
Shares Out
18,208,368
Trailing EPS
$-0.96
Book Value
$1.68
ROE
-55.0%
ROA
-34.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2026 0 -25,094,229 -23,400,949 46,019,461 3,294,499 42,724,962 —
Jun 2025 0 -12,461,203 -12,147,828 46,026,360 3,623,274 42,403,086 -11,451,248
Jun 2024 0 -19,616,621 -19,123,464 19,223,743 5,425,686 13,798,057 -12,605,824
Jun 2023 0 -14,653,292 -13,806,515 27,317,636 4,504,727 22,812,909 -20,035,837
Jun 2022 — — — — — — -12,337,274

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96

Peers — same industry

TickerNameMarket CapLastDaily %
HYFT MindWalk Holdings Corp. $62.96M $1.34 —
RNTX Rein Therapeutics, Inc. $62.20M $0.72 —
XBIT XBiotech Inc. $65.55M $2.15 —
TLPH TALPHERA, INC. $61.77M $1.19 —
ZYBT Zhengye Biotechnology Holding Ltd $61.61M $1.30 —

News headlines (Yahoo Finance, 1h cache)

Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference
2026-09-23 09:07 · Yahoo
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
2026-09-03 11:05 · Yahoo
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
2026-08-12 11:05 · Yahoo
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
2026-08-06 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
2026-07-30 11:25 · Yahoo
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
2026-07-07 11:05 · Yahoo
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
2026-06-09 11:05 · Yahoo
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
2026-05-19 11:25 · Yahoo
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
2026-05-11 11:25 · Yahoo
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
2026-05-07 11:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.